An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

NCT01889433 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis
Hepatitis C

Interventions

DRUG: Algeron
DRUG: Pegasys

Sponsor

Biocad